文献速递头颈CT

口咽及口腔鳞状细胞癌术后调强质子治疗的分次间稳健性

Inter-fraction robustness of intensity-modulated proton therapy in the post-operative treatment of oropharyngeal and oral cavity squamous cell carcinomas.
PubMed 文献 · Br J Radiol · 2019-12-23

本研究评估6例口咽及口腔鳞状细胞癌术后接受多野优化调强质子治疗患者的分次间摆位变异和解剖变化对剂量学的影响,通过每周锥形束CT生成虚拟CT重算剂量。结果显示稳健优化计划对分次间摆位和射程不确定性稳健,靶区D95%至少达处方剂量100%,危及器官平均剂量和脊髓最大剂量在耐受范围内。

要点

  • 术后口咽及口腔鳞癌多野优化调强质子治疗计划对分次间摆位和射程不确定性稳健。
  • 虚拟CT重算的标称计划中靶区D95%至少为处方剂量100%,热点D0.03cc临床可接受。
  • 所有患者危及器官平均剂量和脊髓最大剂量保持在耐受范围内,无患者体重较基线下降≥10%。

核心结论

  • 多野优化调强质子治疗计划在术后口咽及口腔鳞癌患者中,经多次CT扫描评估,对分次间摆位和射程不确定性稳健,且不损害危及器官平均剂量。

研究设计与样本

  • 研究纳入6例接受多野优化调强质子治疗的术后口咽及口腔鳞癌患者,计划以3 mm摆位不确定性和3.5%射程不确定性对临床靶区进行稳健优化。
  • 每周行在线锥形束CT,将计划CT形变至锥形束CT生成虚拟CT并重算计划剂量,虚拟CT计划稳健性评估采用1.5 mm摆位不确定性和3.5%射程不确定性。

诊断标准与关键数值

  • 评估指标包括靶区覆盖率D95%和热点D0.03cc,以及危及器官平均剂量和脊髓最大剂量。
  • 虚拟CT重算的标称计划中,所有计划D0.03cc临床可接受,所有患者D95%至少为处方剂量100%。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate dosimetric consequences of inter-fraction setup variation and anatomical changes in patients receiving multifield optimised (MFO) intensity modulated proton therapy for post-operative oropharyngeal (OPC) and oral cavity (OCC) cancers.

METHODS: Six patients receiving MFO for post-operative OPC and OCC were evaluated. Plans were robustly optimised to clinical target volumes (CTVs) using 3 mm setup and 3.5% range uncertainty. Weekly online cone beam CT (CBCT) were performed. Planning CT was deformed to the CBCT to create virtual CTs (vCTs) on which the planned dose was recalculated. vCT plan robustness was evaluated using a setup uncertainty of 1.5 mm and range uncertainty of 3.5%. Target coverage, D95%, and hotspots, D0.03cc, were evaluated for each uncertainty along with the vCT-calculated nominal plan. Mean dose to organs at risk (OARs) for the vCT-calculated nominal plan and relative % change in weight from baseline were evaluated.

RESULTS: Robustly optimised plans in post-operative OPC and OCC patients are robust against inter-fraction setup variations and range uncertainty. D0.03cc in the vCT-calculated nominal plans were clinically acceptable across all plans. Across all patients D95% in the vCT-calculated nominal treatment plan was at least 100% of the prescribed dose. No patients lost ≥10% weight from baseline. Mean dose to the OARs and max dose to the spinal cord remained within tolerance.

CONCLUSION: MFO plans in post-operative OPC and OCC patients are robust to inter-fraction uncertainties in setup and range when evaluated over multiple CT scans without compromising OAR mean dose.

ADVANCES IN KNOWLEDGE: This is the first paper to evaluate inter-fraction MFO plan robustness in post-operative head and neck treatment.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Hague C, Aznar M, Dong L, et al. Inter-fraction robustness of intensity-modulated proton therapy in the post-operative treatment of oropharyngeal and oral cavity squamous cell carcinomas. Br J Radiol. 2019. PMID: 31845816. doi:10.1259/bjr.20190638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。